{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066971","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.783286+00:00","generated_at":"2026-05-22T04:18:17.326291+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Trevi Therapeutics Q1 net loss $10.3M; positive RIVER trial results; CORAL data expected Q2 2025","bullets":["Net loss of $10.3M ($10.9M YoY); R&D expenses $7.8M, G&A $3.7M.","RIVER Phase 2a positive: 67% cough reduction from baseline, 57% placebo-adjusted (p<0.0001).","CORAL Phase 2b enrollment completed Feb 2025; last patient visit Apr 2025; topline results on track for Q2 2025.","Cash, equivalents and marketable securities $103.3M; runway expected into Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066971","json":"https://secwatch.observer/filing/0000950170-25-066971.json","markdown":"https://secwatch.observer/filing/0000950170-25-066971.md","text":"https://secwatch.observer/filing/0000950170-25-066971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025066971/0000950170-25-066971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025066971/trvi-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:18:17.326291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}